Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q3 FY26 results · Oct–Dec 2025
Lincoln Pharmaceuticals reported revenue from operations of ₹166.32 crore (up 13.5% from Q3 FY25) and net profit of ₹28.60 crore (up 37.7% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 166.32 | 146.55 | +13.5% | 163.36 | +1.8% |
| Other income | 15.15 | 8.97 | +68.8% | 7.23 | +109.4% |
| Total income | 181.47 | 155.52 | +16.7% | 170.60 | +6.4% |
| Profit before tax | 34.72 | 28.68 | +21.1% | 28.81 | +20.5% |
| Net profit for the period | 28.60 | 20.77 | +37.7% | 19.98 | +43.1% |
| EPS, basic (₹) | 14.28 | 10.37 | +37.7% | 9.98 | +43.1% |
| Net margin (%) | 17.2 | 14.2 | 12.2 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 166.32 | 146.55 | +13.5% | 163.36 | +1.8% |
| Other income | 15.15 | 8.97 | +68.8% | 7.23 | +109.4% |
| Total income | 181.47 | 155.52 | +16.7% | 170.60 | +6.4% |
| Profit before tax | 34.72 | 28.68 | +21.1% | 28.81 | +20.5% |
| Net profit for the period | 28.60 | 20.77 | +37.7% | 19.98 | +43.1% |
| EPS, basic (₹) | 14.28 | 10.37 | +37.7% | 9.98 | +43.1% |
| Net margin (%) | 17.2 | 14.2 | 12.2 |
Consolidated
- Filed with BSE
- 12 Feb 2026, 18:24 IST
- Board meeting
- 12 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2026, 18:24 IST
- Board meeting
- 12 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE